For Research Use Only — Not for human or veterinary use.
You must be 21 years of age or older to enter this site. By entering, you confirm that you are 21 or older, and that any products purchased will be used solely for laboratory research purposes — not for human or veterinary consumption, diagnostic, or therapeutic use.
A structural and mechanistic overview of the GLP-1/GIP/glucagon triple-receptor agonist, and the metabolic, hepatic, and structural research domains it has been studied in.
All content on this page is for laboratory and academic reference only. This compound is supplied under a Research Use Only framework for in vitro and preclinical investigation by qualified personnel. Nothing on this page is clinical guidance, and it should not be interpreted as instructions for use in humans or animals.
Retatrutide is a synthetic peptide research compound engineered to act at three distinct G-protein-coupled receptors simultaneously: the GLP-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This "triple agonist" design distinguishes it from single-receptor GLP-1 compounds and dual-receptor GLP-1/GIP compounds studied earlier in the same research area.[4]
Each of the three receptors retatrutide engages contributes a different signaling pathway in the research models studied. GLP-1R activation is associated with glucose-dependent insulin secretion from pancreatic beta cells, suppressed glucagon release, slowed gastric emptying, and appetite-related signaling. GIPR activation contributes complementary insulinotropic signaling. The glucagon receptor (GCGR) component is reported to drive energy expenditure and hepatic fat mobilization — a mechanism not present in earlier single- or dual-receptor incretin research compounds.[4] Cryo-EM structural work published in 2024 confirmed the specific peptide-receptor binding geometry that allows one molecule to activate all three receptor types, identifying both shared and receptor-specific interaction points.[4]
Retatrutide is one of several multi-receptor agonist compounds studied in the metabolic research literature, alongside single-receptor GLP-1 compounds and dual-receptor GLP-1/GIP compounds such as tirzepatide. The distinguishing feature reported for retatrutide specifically is the added glucagon receptor (GCGR) component, which is studied for its contribution to energy expenditure and hepatic fat metabolism beyond what GLP-1/GIP dual agonism alone produces.
A Certificate of Analysis for an R3 (retatrutide) research vial should report, at minimum: confirmed amino acid sequence (typically via mass spectrometry) and net peptide content. Vials should be stored lyophilized at -20°C, protected from light, consistent with handling guidance for the other lyophilized peptides in this catalog.
Retatrutide is studied as a simultaneous agonist at three receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR).[4]
Retatrutide adds a third receptor target, the glucagon receptor (GCGR), reported to contribute additional energy-expenditure and hepatic fat-metabolism effects beyond GLP-1/GIP dual agonism alone.
Cryo-EM studies published in 2024 resolved how a single retatrutide molecule adopts the binding geometry needed to activate all three of its target receptors.[4]
A COA for an R3 research vial should report confirmed amino acid sequence and net peptide content, consistent with the documentation standard used across this catalog.
No. R3 is supplied strictly under a Research Use Only framework for laboratory and preclinical investigation, and none of the studies referenced here involve clinical administration guidance outside of their own regulated trial protocols.
A research overview of the gastric-derived pentadecapeptide BPC-157, its proposed VEGFR2/angiogenesis and growth-hormone-receptor mechanisms, and the tissue-repair, GI, and neurological research domains where it has been studied.
Chemistry, proposed mechanism, and the research domains — cardiac, ophthalmic, and general tissue repair — where the Thymosin Beta-4 fragment appears most in the literature.
How the copper-binding tripeptide complex is structured, its proposed gene-expression and tissue-remodeling mechanisms, and the dermal, antioxidant, and aging research domains it has been studied in.